Abstract 1753P
Background
In up to 30% of gastrointestinal (GI) malignancies, fluoropyrimidines (FP) are associated with severe adverse drug reactions (ADRs). Dihydropyrimidine dehydrogenase (DPYD), is a polymorphic gene involved in FP catabolism. The identification of deleterious variants associated with increased toxicity is recommended before treatment initiation [c.1905+1G>A (*2A); c.1679T>G (*13); c.1129-5923C>G (*IVS10); c.2846A>T (*949) or during treatment in case of ADR [c.2194G>A (*6)]. The estimated prevalence of DPYD deficient genotypes in the European population is <8%. This study aimed to determine the prevalence and implication of systematic DPYD testing in an unselected population with GI tumours.
Methods
The germline DPYD test was conducted on a consecutive series of 1000 pts diagnosed with GI malignancies at our Department between June 2020 and December 2022, candidates for FP for colorectal (CRC 69%), gastroesophageal (GEC 15%), biliopancreatic (BPC 12%), other GI tumours (4%) or double GI malignancy (<1%).
Results
Overall, 819 pts (82%) were DPYD wild type (WT) and 181 (18%) had a deleterious DPYD variant. Among DPYD mutated pts, 134 had CRC (74%), 23 GEC (13%), 17 BPC (9%), 5 other GI tumours (2%) and 1 had CRC and GEC (1%). 184 deleterious variants were observed in 181 pts, the most prevalent was DPYD *6 (N=146 15%) (Table). In 4 pts *6 coexisted with other variants, requiring dose personalization. Of 133 pts enrolled in interventional trials including FP treatment, 24 (18%) reported a deleterious variant: 2A N=1, IVS10 N=2, *6 N=21.
Table: 1753P
DPYD status | N= 1000 | % | FP dosea |
DPYD WT | 819 | 82% | 100% |
DPYD6_c2194G>A homozygosis heterozygosis | 146 * 5 141 | 15% | 70% 85% |
IVS10_1129_5923c>G | 20 | 2% | 50-70% |
DPYD2A_1905+1G>A | 12 | 1% | 50% |
DPYD949_c2846A>T | 5 | <1% | 50% |
DPYD13_c1679T>G | 2 | <1% | 50% |
a recommended dose based on SIF and CPIC guidelines *4 patients presented a double heterozygosis DPYD6 and *2A (N=1), FP dose <50% DPYD6 and c*949 (N=1), FP dose <50% DPYD6 and *IVS10 (N=2), FP dose 50%FP= fluoropyrimidines, WT=wild type
Conclusions
Our large cohort of GI pts revealed a higher prevalence of deleterious DPYD variants compared to previous reports. DPYD*6 was the most frequent genotype and, at a low rate, occurred with other variants requiring major dose adjustments. To prevent severe ADR and to adequately report toxicity and changes in pts' quality of life, our data suggest that DPYD assessment should be mandatory and included in all FP-based clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale.
Funding
Has not received any funding.
Disclosure
C. Cardone: Financial Interests, Personal and Institutional, Advisory Board: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23